The Power of Automation: How Robotics Can Dramatically Reduce Cell Therapy Manufacturing Costs and Scale Patient Access

There’s an elephant in the room when it comes to cell therapy. Hundreds of thousands of patients are in need of these life saving therapies - but the vast majority can’t access the treatment. This is because cell therapy manufacturing is reliant on a highly-skilled and limited labor pool, which results in prohibitively high prices and lack of availability and affordability for most patients. 

Given approximately half of cell therapy manufacturing costs are driven by these labor challenges, bringing cell therapy scalability within reach requires cutting-edge automation. To meet this need, Multiply Labs launched a robotic system for cell therapy manufacturing that is proven to match the performance and reduce the costs of a manual process. This session from Fred Parietti, Ph.D., Co-founder and CEO of Multiply Labs will cover:

• How robotics radically improves the unit economics of cell therapy manufacturing. 
  • Estimates based on scientifically peer-reviewed industry data show that this technology can reduce the cost of typical GMP-level cell therapy manufacturing processes by 70%, on a per-product basis. 
• The power of automation to increase throughput and accelerate production timelines - for example, think of 18 products per incubator hosted in parallel, vs. one or two in a manual process. 
• How the robotic system overcomes potential regulatory and process barriers by operating market-leading GMP instruments that are already deployed to manufacture all currently approved cell therapies. This ensures manufacturers do not need to significantly change their existing processes. 
• Insight into the partnership between Multiply Labs and GenScript to automate the cell isolation phase of cell therapy manufacturing, reducing the complexity of this laborious process.
• The benefits of robotics when it comes to minimizing contamination risk and reducing human error. 
• How manufacturers can ensure they have the flexibility to automate any part of the process, while using less space to get the job done and ensuring the approach is future-proof.

It is critical that we expand patient access to these life-changing treatments. This session will explore the cutting-edge developments made this year in finally bringing automation to cell therapy manufacturing.